No consensus on crowded MS drug field
Posted: Wed Sep 04, 2013 2:40 am
When the American Academy of Neurology (AAN) published its five “Choosing Wisely” recommendations earlier this year, recommendation No. 4 was the following: “Don’t prescribe interferon-β or glatiramer acetate [Copaxone, Teva] to patients with disability from progressive, nonrelapsing forms of multiple sclerosis.”
Several prominent neurologists with expertise in MS criticized the recommendations soon after they were published online in the Feb. 20, 2013 edition of Neurology (doi: 10.1212/WNL.0b013e31828aab14). The specialists clearly were miffed at the proscription against the two injectable MS drugs, posting multiple comments on the “WriteClick” section of Neurology’s website. “This is an oversimplified recommendation that we strongly feel needs to be more nuanced,” argued representatives of the AAN’s Multiple Sclerosis Working Group. “Progressive MS patients with superimposed relapses can still benefit from these agents.........” - Read More - http://www.ms-uk.org/index.cfm/MSnews
Several prominent neurologists with expertise in MS criticized the recommendations soon after they were published online in the Feb. 20, 2013 edition of Neurology (doi: 10.1212/WNL.0b013e31828aab14). The specialists clearly were miffed at the proscription against the two injectable MS drugs, posting multiple comments on the “WriteClick” section of Neurology’s website. “This is an oversimplified recommendation that we strongly feel needs to be more nuanced,” argued representatives of the AAN’s Multiple Sclerosis Working Group. “Progressive MS patients with superimposed relapses can still benefit from these agents.........” - Read More - http://www.ms-uk.org/index.cfm/MSnews